Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.46 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.46 |
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.36 |
| ▸ | OPRD1 known ✓ | P41143 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062713 | 0.90 | SLC6A4 (0.52) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL5107087 | 0.89 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL7210033 | 0.83 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| Cadaverine Tartrate SCHEMBL3542909 | 0.77 | SLC6A3 (0.48) | SLC6A2SLC6A4SLC6A3HTR6OPRM1 | |
| SCHEMBL3061086 | 0.76 | SIGMAR1 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3060519 | 0.71 | HTR1A (0.35) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL6709876 | 0.69 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL6490964 | 0.69 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL6502156 | 0.67 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3NOS3NOS1 | |
| SCHEMBL6498586 | 0.66 | SLC6A4 (0.53) | SLC6A2SLC6A4SLC6A3NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781456-B2 | Enantiomers of 3-heteroaryl-8H-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-08-24 | — | — | US | disclosed |
| US-20080214820-A1 | Enantiomers of 3-Heteroaryl-8H-8-Azabicyclo (3.2.1) Oct-2-Ene and their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-09-04 | — | — | US | disclosed |
| EP-1828173-A1 | ENENTIOMERS OF 3-HETEROARYL-8H-8-AZABICYCLO(3.2.1)OCT-2-ENE AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064031-A1 | ENANTIOMERS OF 3-HETEROARYL-8H-8-AZABICYCLO(3.2.1)OCT-2-ENE AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214820-A1 | Enantiomers of 3-Heteroaryl-8H-8-Azabicyclo (3.2.1) Oct-2-Ene and their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A3 5/4885OPRM1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.